Fosamax | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Fosamax
Health Canada Patents

PharmaCompass Sponsored Ads

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Fosamax

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

47 API Suppliers, 24 USDMF, 13 CEP/COS, 6 JDMF, 10 EU WC, 13 KDMF, 11 NDC API, 19 Listed Suppliers, $ API Reference Price

47 API Suppliers
24 USDMF
13 CEP/COS
6 JDMF
10 EU WC
13 KDMF
11 NDC API
19 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

233 FDF Dossiers, 64 FDA Orange Book, 107 Europe, 24 Canada, 8 Australia, 3 South Africa, 27 Listed Dossiers

233 FDF Dossiers
64 FDA Orange Book
107 Europe
24 Canada
8 Australia
3 South Africa
27 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 70MG BASE, TABLET;ORAL - EQ 70MG BASE;2,800 IU, TABLET;ORAL - EQ 70MG BASE;5,600 IU

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 70MG BASE
TABLET;ORAL - EQ 70MG BASE;2,800 IU
TABLET;ORAL - EQ 70MG BASE;5,600 IU

RELATED EXCIPIENT COMPANIES

4 Rochem International Inc, 18 SPI Pharma, 6 DKSH, 1 Pharm-RX Chemical, 7 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 2 Actylis, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 7 BASF, 1 Bioplus Life Sciences, 7 DFE Pharma, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 26 Kerry, 3 Lonza Capsugel, 12 Microlex e.U, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 18 Roquette, 1 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

75 Fillers, Diluents & Binders, 29 Disintegrants & Superdisintegrants, 28 Direct Compression, 24 Taste Masking, 19 Granulation, 19 Thickeners and Stabilizers, 17 Co-Processed Excipients, 15 Chewable & Orodispersible Aids, 14 Lubricants & Glidants, 8 Empty Capsules, 7 Coating Systems & Additives, 6 Parenteral, 5 Controlled & Modified Release, 3 API Stability Enhancers, 3 Solubilizers, 3 Emulsifying Agents, 2 Topical, 2 Rheology Modifiers, 1 Film Formers & Plasticizers, 1 Surfactant & Foaming Agents

75 Fillers, Diluents & Binders
29 Disintegrants & Superdisintegrants
28 Direct Compression
24 Taste Masking
19 Granulation
19 Thickeners and Stabilizers
17 Co-Processed Excipients
15 Chewable & Orodispersible Aids
14 Lubricants & Glidants
8 Empty Capsules
7 Coating Systems & Additives
6 Parenteral
5 Controlled & Modified Release
3 API Stability Enhancers
3 Solubilizers
3 Emulsifying Agents
2 Topical
2 Rheology Modifiers
1 Film Formers & Plasticizers
1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 25 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
25 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 120 Finished Drug Prices, 5 Annual Reports

4 US Medicaid Prescriptions
120 Finished Drug Prices
5 Annual Reports

MARKET PLACE

10 APIs, 1 FDF Dossiers

10 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

1 US Patents, 17 Health Canada Patents

1 US Patents
17 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP, 4 JP, 1 Others

2 EDQM
1 USP
4 JP
1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 179 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

17 All

01 12Merck Canada Inc.

02 5Blank

filter Patent Reset all filters

17 All

01 52018477

02 42149052

03 12190148

04 52221417

05 22294595

filter Product Reset all filters

17 All

01 12Alendronate Sodium

02 5Blank

filter Dosage Reset all filters

17 All

01 3Solution

02 9Tablet

03 5Blank

filter Exp Date Reset all filters

17 All

01 52010-06-07

02 42013-11-17

03 12015-05-12

04 52016-06-03

05 22018-07-17

Alendronate Sodium

Product Main Page

01

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-11-17

Date Granted : 2003-03-25

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2149052

Filing Date : 1993-11-17

Strength per Unit : 10 mg/tablet

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-11-17

Date Granted : 2003-03-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-11-17

Date Granted : 2003-03-25

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2149052

Filing Date : 1993-11-17

Strength per Unit : 40 mg/tablet

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-11-17

Date Granted : 2003-03-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-11-17

Date Granted : 2003-03-25

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2149052

Filing Date : 1993-11-17

Strength per Unit : 5 mg/tablets

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-11-17

Date Granted : 2003-03-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2013-11-17

Date Granted : 2003-03-25

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2149052

Filing Date : 1993-11-17

Strength per Unit : 70 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2013-11-17

Date Granted : 2003-03-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-05-12

Date Granted : 2006-02-14

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2190148

Filing Date : 1995-05-12

Strength per Unit : 70 mg / 75 ml

Dosage Form : Solution

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2015-05-12

Date Granted : 2006-02-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-06-03

Date Granted : 2002-04-30

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2221417

Filing Date : 1996-06-03

Strength per Unit : 70 mg / 75 ml

Dosage Form : Solution

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-06-03

Date Granted : 2002-04-30

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-07-17

Date Granted : 2001-08-21

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2294595

Filing Date : 1998-07-17

Strength per Unit : 70 mg / 75 ml

Dosage Form : Solution

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-07-17

Date Granted : 2001-08-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-06-03

Date Granted : 2002-04-30

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2221417

Filing Date : 1996-06-03

Strength per Unit : 10 mg/tablet

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-06-03

Date Granted : 2002-04-30

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-06-03

Date Granted : 2002-04-30

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2221417

Filing Date : 1996-06-03

Strength per Unit : 40 mg/tablet

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-06-03

Date Granted : 2002-04-30

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

Merck Canada Inc.

Alendronate Sodium

BioAsia

Not Confirmed

Merck Canada Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-06-03

Date Granted : 2002-04-30

Alendronate Sodium

Brand Name : FOSAMAX

Patent Number : 2221417

Filing Date : 1996-06-03

Strength per Unit : 5 mg/tablets

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-06-03

Date Granted : 2002-04-30

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!